Resonance Health Limited’s FerriScan® R2-MRI Receives FDA Marketing Authorization as the First Imaging Companion Diagnostic Device for Exjade® in Patients With Non-Transfusion-Dependent Thalassemia (NTDT)

Published: Jan 31, 2013

SAN DIEGO--(BUSINESS WIRE)--The U.S. Food and Drug Administration recently announced the authorization of FerriScan® R2-MRI1 to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia2. Exjade® (deferasirox) is a drug marketed by Novartis to remove excess iron in patients with genetic blood disorders.

Back to news